Medical devices, healthcare technology and the business of care
510(k) clearance · K263380

STAR Apollo Mapping System

Rhythm AI, Ltd. · Decision date Oct 23, 2026

FDA DECISIONK263380

What did the FDA decide?

FDA records K263380 as a 510(k) premarket notification, with a decision dated Oct 23, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Oct 23, 2026

FDA source record

Regulatory record facts

Identifier
K263380
Regulatory pathway
510(k) premarket notification
Product code
DQK
Decision code
SESE
Decision date
Oct 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Computer, Diagnostic, Programmable.

Product code
DQK
FDA device class
2

FDA decision timeline

  1. K263380 received

    Application receipt date recorded by FDA.

  2. K263380 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DQK

Product / regulatory recordCompanyPathwayDecision dateSource
Merge Healthcare Incorporated510(k) clearanceNov 5, 2026FDA
Catheter Precision, Inc.510(k) clearanceOct 30, 2026FDA
PulseAI, Ltd.510(k) clearanceOct 27, 2026FDA
Centerline Biomedical510(k) clearanceOct 1, 2026FDA
Wellysis Corp.510(k) clearanceSep 25, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Rhythm AI, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
London

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records